-
2025 ICML | Professor Shunan Qi on Risk-Adapted Radiotherapy Strategies for Early-Stage NK/T-Cell Lymphoma
Oncology Frontier – Hematology Frontier: Professor Qi, you have extensive experience in lymphoma radiotherapy. With the integration of modern systemic therapies in early-stage lymphoma, how has this affected the planning…
-
Voices from China in Lugano | Showcasing the Power of Chinese Solutions: Prof. Qingqing Cai’s Team Presents P-GEMOX + PD-1 and L-CHOP Regimens at ICML
Current Systemic Strategies and Emerging Therapies in ENKTCL Oncology Frontier – Hematology Frontier: What are the current frontline systemic therapies for ENKTCL in China and abroad? How do these treatments…
-
2025 ICML | Professor Jun Zhu: China–Europe Synergy Sparks a New Era — Advancing Global Collaboration in Lymphoma Research
Oncology Frontier – Hematology Frontier invited Professor Jun Zhu of Peking University Cancer Hospital to provide expert insights into the latest developments in China–Europe collaborative lymphoma research and to share…
-
CTH 2025 | Prof. Defu Zeng: Pathogenesis and Therapeutic Advances in Chronic Graft-Versus-Host Disease
Oncology Frontier-Hematology Frontier：In your research, what new cellular and molecular mechanisms of chronic graft-versus-host disease (cGVHD) have been identified? Compared with previous understandings, what major breakthroughs do these new findings…
-
Five-Year CheckMate 649 Update: Nivolumab Plus Chemo Extends Survival for Chinese Gastric Cancer Patients
Introduction Gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma are among the most aggressive malignancies, particularly in their advanced stages. The CheckMate 649 trial previously established nivolumab plus chemotherapy as a superior first-line treatment compared to chemotherapy alone. With five years of follow-up, this latest analysis provides crucial insights into long-term survival, disease progression, and…
-
MAINTAIN Trial: Shaping Post-CDK4/6i Strategies in HR+/HER2− Metastatic Breast Cancer
Although published in 2023, the MAINTAIN trial remains a key reference in the evolving management of HR+/HER2− metastatic breast cancer following progression on CDK4/6 inhibitors.In this randomized, placebo-controlled phase II…
-
ESMO China Voice | Dr. Cheng Huang & Dr. Rongbo Lin: Global First Evidence Shows IV IPCA Outperforms Oral Morphine for Severe Cancer Pain, Potentially Changing Guidelines and Transforming Pain Management
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. A Phase III randomized controlled trial (SYLT-021), led by Dr. Rongbo Lin’s team from the Department of Gastrointestinal Oncology, Fujian Cancer Hospital, was selected as one of six Proffered Paper oral presentations in the palliative care session. This study compared…
Connecting Medical Expertise through Media
